AstraZeneca (MEX:AZNN) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:AZNN AstraZeneca PLC MEX:AZNN
84 GF Score
Price MXN1,628.00
GF Value MXN1,864.39
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


AstraZeneca  (MEX:AZNN) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


AstraZeneca Cyclically Adjusted PS Ratio Related Terms


AstraZeneca Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted PS Ratio Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 6.01 4.77 5.19 5.89

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.65 4.82 4.93 5.74 5.55

MEX:AZNN vs LLY, JNJ, ABBV: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


MEX:AZNN
84GF Score
AstraZeneca PLC MEX:AZNN
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 is calculated as:

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=85.989/140.8000*140.8000
=85.989

Current CPI (Mar. 2026) = 140.8000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 40.043 101.000 55.822
201609 42.217 101.500 58.563
201612 43.765 102.200 60.295
201703 43.339 102.700 59.417
201706 36.976 103.500 50.302
201709 43.857 104.300 59.205
201712 43.216 105.000 57.951
201803 38.275 105.100 51.276
201806 43.511 105.900 57.850
201809 42.876 106.600 56.632
201812 56.709 107.100 74.553
201903 45.476 107.000 59.841
201906 42.445 107.900 55.387
201909 49.237 108.400 63.954
201912 51.786 108.500 67.202
202003 51.175 108.600 66.348
202006 56.196 108.800 72.724
202009 56.810 109.200 73.250
202012 61.997 109.400 79.791
202103 64.860 109.700 83.248
202106 62.439 111.400 78.918
202109 66.050 112.400 82.739
202112 81.300 114.700 99.800
202203 74.810 116.500 90.414
202206 69.223 120.500 80.885
202209 71.302 122.300 82.088
202212 70.767 125.300 79.521
202303 65.054 126.800 72.237
202306 64.761 129.400 70.466
202309 62.858 130.100 68.028
202312 67.644 130.500 72.983
202403 69.055 131.600 73.883
202406 71.501 133.000 75.694
202409 82.197 133.500 86.692
202412 95.789 135.100 99.830
202503 88.831 136.100 91.899
202506 90.535 138.400 92.105
202509 90.661 138.900 91.901
202512 90.769 139.900 91.353
202603 85.989 140.800 85.989

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is AstraZeneca (MEX:AZNN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of MXN1,628.00 is trading 12.7% below its estimated GF Value™ of MXN1,864.39.

Key valuation signals for MEX:AZNN:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: MXN1,864.39 vs. price of MXN1,628.00 (12.7% below fair value)
  • GF Score™: 84/100 with 1 warning sign

No single metric tells the full story. See the MEX:AZNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
84GF Score

Get the complete analysis for MEX:AZNN

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,628.00
Price
MXN1,864.39
GF Value